- Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns
- Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated
- EDP2939 Phase 2 data in psoriasis anticipated in 2H 2023
Evelo Biosciences, a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that its first extracellular vesicle (EV) product candidate, EDP2939, has progressed to dosing in a Phase 2 psoriasis clinical trial after completing a safety and tolerability review from a first cohort of human volunteers. Safety and tolerability assessment of multiple ascending dose cohorts continues.
“This is a milestone for both EDP2939 and Evelo’s broader platform of orally-delivered EVs,” said Evelo’s Chief Medical Officer, Duncan McHale, M.B.B.S., Ph.D. “It is the first time that a potential bacterial EV medicine has been delivered orally to humans. Safety and tolerability are a central part of Evelo’s vision to develop medicines to treat all stages and all types of inflammatory diseases. We have now started dosing in the Phase 2 part of the trial in patients with moderate psoriasis.”
Mark Bodmer, Ph.D., President of R&D and Chief Scientific Officer of Evelo added, “EVs and EDP2939 show great promise as a new type of SINTAX medicine with potential for biologic-like efficacy based on three factors: (1) the high intrinsic potency of EVs in preclinical models; (2) the number and concentration of EVs that can be delivered in a single capsule; and (3) the delivery to the target site of the proximal small intestine. We look forward to reporting EDP2939 psoriasis efficacy results, expected in the second half of this year.”
Source – Globe Newswire